Harnessing the Full Potential of Frontline Immunotherapy in Advanced NSCLC: Proceedings from a Clinical Olympics℠

Program Overview

The advent of frontline immunotherapy has significantly extended survival for certain patients with metastatic non-small cell lung cancer (NSCLC). As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Jared Weiss, Prof. Aleš Ryška, and Dr. Mihaela Aldea provide privileged insights into the nuances of biomarker testing, optimal regimen selection, and management of immune-related adverse events.

Credit Expired

Target Audience

Medical oncology and pulmonology clinicians managing patients with advanced NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize molecular testing in patients with advanced non-small cell lung cancer (NSCLC) as a guide for frontline treatment selection
  • Select optimal frontline immune checkpoint inhibitor regimens in appropriate patients with advanced NSCLC
  • Manage potential immune-related adverse events in patients with advanced NSCLC receiving first-line immunotherapy

Activity Faculty

Jared M. Weiss, MD

Jared M. Weiss, MD

Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States

Ales Ryska_Faculty Headshot_1200x1500

Prof. MUDr. Aleš Ryška, MD, PhD

Head, Fingerland Department of Pathology
Charles University Medical Faculty
Hradec Králové University Hospital
Prague, Czech Republic


Mihaela Aldea, MD, PhD

Associate Professor, Medical Oncology
Paris-Saclay University
Gustave Roussy
Villejuif, France


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources